SHOP is up 14% on the week to $147.74, yet the options market is flashing its most defensive posture in over a year — a divergence that makes this week's setup unusually interesting.
The clearest signal comes from options. Put/call demand has turned sharply more cautious, with the PCR running at 0.90 — more than two standard deviations above its 20-day mean of 0.56. That is the highest defensive reading the market has registered for SHOP in the past 12 months, with only Monday's intraday reading of 1.10 topping it. The stock's 7% single-day gain on Tuesday clearly spooked some holders into buying protection, even as the rally extended. It is rare to see this degree of hedging layered onto a name that has just posted one of its best weekly moves of the year.
The lending market tells an entirely different story. Borrow availability is essentially unlimited — the pool is so deep that the metric caps at the top of the range, and has remained there every trading day for months. Cost to borrow is a modest 1.05%, up roughly 10% on the week but still well below any level that would concern a short seller. Short interest itself is just 1.5% of the free float, down 5% in a single session on Tuesday and off nearly 7% over the past month. Bears have been trimming, not building. There is no meaningful short-side pressure here — the squeeze narrative simply does not apply.
The Street is broadly constructive. Wedbush reiterated its Outperform rating and $176 target this morning, and Piper Sandler raised its target two weeks ago to $180 from $172 while staying Overweight. Bernstein also initiated coverage at Outperform with a $160 target earlier this month — all of this coming in a tight cluster after the August earnings print, which sent the stock up nearly 20% in a single session. The consensus sits firmly at Buy across 30 covering analysts, with targets clustering in the $160-$200 range. The bull case rests on payment and shipping monetisation, strong gross profit and free cash flow margins, and forward earnings momentum that ranks in the 92nd percentile on EPS surprise. The bear case centres on cash tax headwinds — rising to roughly 28% of EBIT versus 13% last year — and the question of whether the Street's 2027 revenue model of ~$19 billion is too ambitious given slowing net-new revenue growth. Valuation is unambiguously stretched: the PE is running at 64x and EV/EBITDA above 53x, both having moved higher with the week's rally.
Institutional ownership data adds useful colour. Capital Research remains the largest institutional holder at 7.7% of shares, having added over 1.3 million shares in the most recent period. Founder and CEO Tobias Lütke holds 6.1% of the company — but filed a sell of roughly 64,000 shares in aggregate on September 2 at prices around $139-$140. That disclosure arrived before this week's rally and carries trade-significance scores of just 1, suggesting routine plan-driven activity rather than a conviction-driven exit. BlackRock has also been a steady incremental buyer, moving to 5.1% of class in its most recent 13G amendment filed in July. No 13D activist is on the register.
The next earnings event is pencilled in for November 3. After the August print produced a 20% single-day move and a 22% five-day follow-through, the bar has been reset considerably higher. What to watch into that date: whether the hedging activity visible in this week's elevated PCR persists or fades as the stock digests the latest leg higher, and whether the cost-to-borrow drift continues or reverses as the short book — already at a multi-month low — reaches an equilibrium level.
See the live data behind this article on ORTEX.
Open SHOP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
